Products

Nuflow. Nasal cannula for high flow oxygen therapy

"" ""

Product benefits

  • High degree of patient comfort
  • Low noise level and system stagnation pressure
  • Individual fixation, gentle to the skin
  • Anatomically adapted shape of the prongs 
In this video we shortly demonstrate how to correctly use the Nuflow nasal cannulas. Nuflow is a patient interface for high flow oxygen therapy of neonates.

Area of application

The medin Nuflow is compatible with medinCNOmini, medin-NC3 and medin blender. We recommend the use of a pressure relief valve when using the medin blender. 

""

Soft and kind to the skin

The medin Nuflow high flow nasal cannula is made out ouf soft and skin compatible silicone which helps to perfectly balance therapy and wearing comfort. Even the smallest cannula size provides flow rates up to 8 LPM and therefore, meet the current knownledge of the application of high flow oxygen therapy in          neonatology (Roehr CC, Yoder BA, Davis PG, Ives K. Evidence Support and Guidelines for Using Heated, Humidified, High-Flow Nasal Cannulae in Neonatology: Oxford Nasal High-Flow Therapy Meeting, 2015. Clin Perinatol. 2016;43(4):693-705. doi:10.1016/j.clp.2016.07.0061​).  

Further cannula sizes can be used for babies and infants in combination with a suitable ventilator, for example from Hamilton Medical

""

Choose the appropriate size

At least 50% of the nostril remains unobstructed to: 

  • reduce possible overpressure 
  • make exhalation easier 
  • ensure optimum rinsing 

Evidence Support and Guidelines for Using Heated, Humidified, High-Flow Nasal Cannulae in Neonatology: Oxford Nasal High-Flow Therapy Meeting, 2015.

Roehr CC, Yoder BA, Davis PG, Ives K. Evidence Support and Guidelines for Using Heated, Humidified, High-Flow Nasal Cannulae in Neonatology: Oxford Nasal High-Flow Therapy Meeting, 2015. Clin Perinatol. 2016;43(4):693-705. doi:10.1016/j.clp.2016.07.006

Nasal high-flow therapy (nHFT) has become a popular form of noninvasive respiratory support in neonatal intensive care units. A meeting held in Oxford, UK, in June 2015 examined the evidence base and proposed a consensus statement. In summary, nHFT is effective for support of preterm infants following extubation. There is growing evidence evaluating its use in the primary treatment of respiratory distress. Further study is needed to assess which clinical conditions are most amenable to nHFT support, the most effective flow rates, and escalation and weaning strategies. Its suitability as first-line treatment needs to be further evaluated.